The aim of COBALT is the development of technological platforms ("biological twin") and predictive algorithms ("digital twin") of physiological barriers for the screening, monitoring and personalized treatment of complex pathological contexts such as neurodegenerative diseases and autoimmune diseases. Hardware platforms based on microfluidic technologies of the two most important barriers for human pathophysiology will be created and validated: the blood-brain barrier and the endothelial barrier.
